Plain-English translation of NCT05047094 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new approach to treat advanced head and neck squamous cell carcinoma by combining two treatments: tiny radioactive seeds (called DaRT) that are temporarily implanted directly into the tumor, and , an immunotherapy medication that helps your immune system fight cancer. The seeds stay in place for about 2–3 weeks and are then removed, while the medication continues as standard treatment.
Head and neck cancers that have spread or cannot be surgically removed are very difficult to treat and often come back. This trial is exploring whether combining local radiation directly in the tumor with the medication can improve outcomes for patients who have limited other options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will undergo a procedure to have small radioactive seeds implanted into your tumor under medical supervision. The seeds will be left in place for 2–3 weeks and then removed. At the same time, you will receive intravenously as part of your regular cancer treatment. Your progress will be monitored with imaging scans (like CT or MRI) every 6 weeks starting at day 42 after the implant to see how well the treatment is working.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Israel